Aspart
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Type1 Diabetes Mellitus
Conditions
Type1 Diabetes Mellitus
Trial Timeline
Apr 12, 2018 → Nov 1, 2020
NCT ID
NCT04409587About Aspart
Aspart is a approved stage product being developed by Novo Nordisk for Type1 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT04409587. Target conditions include Type1 Diabetes Mellitus.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04409587 | Approved | Completed |
Competing Products
11 competing products in Type1 Diabetes Mellitus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High Dose | Precigen | Phase 1/2 | 36 |
| Insulin Lispro | Eli Lilly | Phase 1 | 33 |
| LY900014 + Insulin Lispro | Eli Lilly | Phase 2 | 52 |
| Selumetinib | AstraZeneca | Pre-clinical | 23 |
| Dapagliflozin + Placebo Oral Tablet | AstraZeneca | Phase 1 | 33 |
| Semaglutide Pen Injector + Placebo | Novo Nordisk | Phase 2 | 51 |
| Insulin glargine new formulation HOE901 | Sanofi | Phase 1 | 32 |
| Insulin glulisine (U300) + Insulin glulisine + Insulin aspart + NPH insulin + Glucagon + Glucose + Heparin | Sanofi | Phase 1 | 32 |
| verapamil 120mg tablet + placebo | Dexcom | Phase 3 | 74 |
| UP421 | Sana Biotechnology | Phase 1 | 28 |
| XeriSol glucagon | Xeris Pharmaceuticals | Phase 1 | 28 |